Cizzle Brands Strengthens U.S. Footprint of CWENCH Hydration™ With Availability at United Supermarkets in Texas
Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) (the 'Company' or 'Cizzle Brands'), is pleased to announce that the hydration mix format of its flagship product CWENCH Hydration™ is being carried by United Supermarkets, a grocery chain with a substantial presence in central and northern Texas, which includes urban areas such as Lubbock, Amarillo, Odessa, and Abilene.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250410440469/en/
The 10-count hydration mix format of CWENCH Hydration™ is sold by United Supermarkets in Texas.
As of April 2025, the original four flavours of CWENCH Hydration™ (Blue Raspberry, Cherry Lime, Rainbow Swirl, and Berry Crush) are being sold in the 10-count hydration mix packet format in-store at United Supermarkets. All four SKUs are also available through United Supermarkets' online ordering portal.
United Supermarkets is part of The United Family, which is a wholly-owned subsidiary of S&P MidCap 400 ® component Albertsons Companies, Inc., one of the largest supermarket chains in the United States. The United Family operates 99 stores under five different banners, serving 1.5 million guests per week in 54 Texas and New Mexico communities.
So far in its Fiscal 2025 year, 20% of the Company's $5.64 million in net sales took place in the United States. As Cizzle Brands seeks to further scale the market share of CWENCH Hydration™ across North America, the Company has undertaken initiatives (such as becoming the Official Hydration Partner of USA Hockey) to fortify its U.S. footprint, alongside the strategic selection of retail partners such as United Supermarkets in key geographic areas.
CWENCH Hydration™ is already carried across the Life Time chain of athletic country clubs in the United States, including at over 30 locations across the state of Texas. This placement with United Supermarkets is therefore expected to complement the brand's existing presence in several Texas regions.
Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, 'Each market is different in terms of the optimal tactics for launching a sports nutrition brand. This is why we're taking a patient, strategic, and selective approach to establishing CWENCH Hydration™ in specific U.S. markets, partnering with established and well-known local chains who have the reach and the capabilities to introduce the product to our target audience. We are proud to have CWENCH Hydration™ carried by United Supermarkets in Texas, and we look forward to building out our distribution pipeline in this dynamic and high-growth region of the United States.'
About Cizzle Brands Corporation
Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 1,800 locations in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport ® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle.
For more information about Cizzle Brands, please visit: https://www.cizzlebrands.com/
For more information about CWENCH Hydration™, please visit: https://www.cwenchhydration.com
On behalf of the Board of Directors of the Company,
CIZZLE BRANDS CORPORATION
'John Celenza'
John Celenza, Founder, Chairman, and Chief Executive Officer
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company.
Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 days ago
- Cision Canada
enCore Energy Announces Filing of Early Warning Report
DALLAS, June 20, 2025 /CNW/ - enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the"Company" or "enCore"), America's Clean Energy Company ™, announces that it has disposed of 170,000,000 common shares in the capital of Anfield Energy Inc. (" Anfield") (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) in a private agreement at a price of $0.115 per share for aggregate proceeds of $19,550,000 (Canadian dollars). Immediately following the disposition, enCore holds or controls no common shares of Anfield. The disposition represents a 14.73% decrease in enCore's ownership or control over the outstanding common shares of Anfield on an undiluted basis. enCore does not currently hold or control any securities of Anfield. Since enCore's last early warning report dated January 15, 2024, enCore's holdings have decreased by an approximate 16.02% of the outstanding common shares of Anfield on an undiluted basis. enCore disposed of the shares of Anfield in a private transaction. enCore may, depending on market and other conditions, increase beneficial ownership of the Company's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities. The disclosure respecting enCore's shareholdings contained in this news release is made pursuant to National Instrument 62-103 and a report respecting the above disposition will be filed with the applicable securities commissions and will be available for viewing at A copy of the report may also be obtained by contacting Robert Willette, Acting Chief Executive Officer, or at [email protected]. About enCore Energy Corp. enCore Energy Corp., America's Clean Energy Company ™, is committed to providing clean, reliable, and affordable fuel for nuclear energy as the only United States uranium company with multiple central processing plants in operation. enCore operates the 100% owned and operated Rosita CPP in South Texas and the 70/30 joint venture Alta Mesa CPP with Boss Energy Ltd., with enCore operating as the project manager. The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore solely utilizes ISR for uranium extraction, a well-known and proven technology co-developed by the leaders at enCore Energy. Following upon enCore's demonstrated success in South Texas, future projects in enCore's planned project pipeline include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming. The Company holds other assets including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impact from corporate developments.
Cision Canada
2 days ago
- Cision Canada
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan."This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Cision Canada
2 days ago
- Cision Canada
AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape Français English
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025 /CNW/ -- Equity Insider News Commentary – Amid the wave of new AI-powered innovations in healthcare, so far ambient scribes have emerged as the breakout use case. As the range of AI uses for the healthcare sector continues to grow, experts are analyzing the potential ROI on their implementation, and how much they'll benefit early adopters. Healthcare leaders are already seeing improvements, such as slashed clinician workloads from voice AI, and the adoption of AI agents to increase efficiency and smarter care delivery. For investors looking for remaining early-mover advantages, there have been several publicly-traded companies with recent developments worthy of capturing their attention, including Avant Technologies, Inc. (OTCQB: AVAI), Spectral AI, Inc. (NASDAQ: MDAI), Palantir Technologies (NADSAQ: PLTR), GE HealthCare Technologies Inc. (NASDAQ: GEHC), and CeriBell, Inc. (NASDAQ: CBLL). Investor interest in private companies is surging, as venture capital continues to pour into the AI-in-healthcare space. In Q1 alone, AI firms accounted for more than half of all digital health funding. Recent raises include $45 million for Ellipsis Health and $28 million for Autonomize AI, both targeting next-gen clinical intelligence. From diagnostics to drug discovery, the pace of innovation is accelerating — and many of these rollouts are now catching the attention of retail investors. One example is the rollout of AI-powered screenings for diabetic retinopathy now underway across Costa Rica, Nicaragua, and Panama. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka's Fischel and La Bomba pharmacy chains. The fast, non-invasive test detects early retinal changes—often before symptoms appear—and delivers secure results within minutes. By embedding the service in retail pharmacies and preparing for a parallel launch in Mexico, the partners are bringing care closer to patients while generating real-world data to support broader commercialization. "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment, connecting every step of the journey," said Vinicio Vargas, CEO of Ainnova Tech and board member of Ai-nova Acquisition Corp. "We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive, the well-being of the diabetic patient." The rollout also gives Avant a timely proof point as it moves to consolidate Vision AI under one roof. Earlier this month, the company signed a non-binding letter of intent to acquire 100% of Ainnova Tech —bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. Management sees the unified cap table as a potential draw for both investors and strategic partners. While the legal teams work through due diligence, engineers are finalizing a low-cost, automated retinal camera built to work seamlessly with the Vision AI platform. Legacy fundus cameras can run into the tens of thousands and typically require skilled operators. Avant's prototype is fully automated, cloud-connected, and designed for a fraction of the cost. If performance holds up to internal testing, the system could enable large-scale diabetic screenings in clinics and low-resource settings—without the need for additional specialist staff. Vision AI is also expanding beyond diabetic eye disease. A patented dementia-risk module —pairing a five-minute blood test with AI pattern recognition—is now in validation, while cardiovascular-risk analytics are advancing through pilot studies across Latin America. Because every new use case plugs into the same software backbone, Avant looks more like a scalable platform than a single-product company. On the financial side, the planned merger would fold all outstanding Ainnova shares into Avant's public float, avoiding cash dilution and fully aligning the combined team's incentives. Management says any future fund-raising would be aimed at three priorities: completing the automated camera, widening pharmacy deployments, and supporting U.S. regulatory milestones. Taken together, the pharmacy roll-out, planned Ainnova acquisition, and imminent camera launch signal a turning point for Avant. What began as an AI incubator is fast becoming a full-stack diagnostics company, complete with proprietary hardware, an expanding library of predictive algorithms, and retail-level distribution partners. If execution matches vision, Vision AI could cut referral delays, open earlier treatment windows, and give resource-strained health systems specialist-grade insight at primary-care prices—turning headline-grabbing tech into tangible patient benefits. Spectral AI, Inc. (NASDAQ: MDAI) continues to advance its DeepView® System, an AI-powered wound imaging platform designed to assess burn healing potential without invasive biopsies. The company's technology was recently spotlighted at the British Burn Association Conference, where new clinical data from UK hospitals showed DeepView® improved detection rates from 61% to 89%. "UK investigators shared valuable advancements with DeepView during the BBA meeting," said Dr. Jeffrey Carter, M.D., Louisiana State University Health Science Center. "Their early clinical experience demonstrated promising sensitivity and specificity results, along with a positive patient experience and a comprehensive evaluation of TBSA (Total Body Surface Area) calculation methods." The system aims to accelerate triage decisions and reduce treatment errors in both civilian and military burn care. Palantir Technologies (NADSAQ: PLTR) has entered into a strategic partnership with TeleTracking Technologies to deliver AI-powered operational insights to hospitals and health systems. The collaboration combines TeleTracking's Operations IQ platform with Palantir's Foundry and AIP, offering real-time visibility into staffing, capacity, and patient flow. "This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of-where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care," said Alex Karp, CEO at Palantir. According to both companies, the platform will unlock real-time visibility across health systems while easing the load on overburdened staff. Executives describe it as a foundational shift toward AI-native operations in healthcare. GE HealthCare Technologies Inc. (NASDAQ: GEHC) has partnered with Stanford Medicine to advance total-body PET/CT technology that incorporates AI into every stage of the imaging process. The system delivers high-resolution, full-body scans in a fraction of the time, while reducing radiation dose for patients. "Our total body PET/CT technology represents the next chapter in our enduring commitment to advancing medical imaging," said Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. "We're proud to collaborate with world-class institutions to explore new clinical frontiers in oncology and beyond. Together with our MIM software solutions, we're designing flexible, AI-enhanced tools that not only aim to enhance diagnostic confidence and operational efficiency but also help clinicians deliver more precise, personalized care that can truly improve patient outcomes." Key to the innovation is a deep-learning reconstruction engine that enhances detail and enables exploratory insights across oncology, cardiology, and neurology. GE HealthCare sees the platform as a foundation for identifying novel biomarkers, guiding treatment, and supporting large-scale clinical research. CeriBell, Inc. (NASDAQ: CBLL) is gaining momentum with its Rapid Response EEG system, which uses artificial intelligence to detect non-convulsive seizures in critical care settings. The company reported over 54,000 patients monitored in Q1 2025 alone, with 70% of seizures identified outside neurology departments—highlighting its utility in high-pressure environments. "We are pleased with our strong start to the year as we further expanded our account base while benefiting from accelerated adoption of the Ceribell system," said co-founder and CEO Jane Chao, Ph.D. "We also look forward to offering our pediatric Clarity algorithm to customers while continuing to invest in our product development pipeline with the goal of ultimately making EEG a new vital sign." With multiple AI modules, including seizure triage and brain function trending, Ceribell is becoming a key player in real-time neurological diagnostics. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
